Patents by Inventor Robert B. Naso
Robert B. Naso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8026109Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: July 14, 2010Date of Patent: September 27, 2011Assignee: Nabi Biopharmaceuticals, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20110217320Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: May 13, 2011Publication date: September 8, 2011Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20110002957Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: July 14, 2010Publication date: January 6, 2011Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7776620Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: July 20, 2007Date of Patent: August 17, 2010Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7449189Abstract: Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.Type: GrantFiled: January 25, 2006Date of Patent: November 11, 2008Assignee: NABI BiopharmaceuticalsInventors: Ali I. Fattom, Robert B. Naso
-
Patent number: 7247502Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: August 3, 2004Date of Patent: July 24, 2007Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7030101Abstract: Compositions and kits comprising combinations of ?-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which ?-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: GrantFiled: February 22, 2002Date of Patent: April 18, 2006Assignee: Nabi BiopharmaceuticalsInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6773891Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 30, 2002Date of Patent: August 10, 2004Assignee: NABI BioPharmaceuticals, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20030165950Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: December 30, 2002Publication date: September 4, 2003Applicant: NABI, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20030113350Abstract: Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide surface antigen from a clinically-significant bacterial strain. The vaccines can be used for active protection in immune-compromised individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure.Type: ApplicationFiled: September 19, 2001Publication date: June 19, 2003Inventors: Ali I. Fattom, Robert B. Naso
-
Patent number: 6518031Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: February 16, 2001Date of Patent: February 11, 2003Assignee: NABIInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20020131969Abstract: Compositions and kits comprising combinations of &bgr;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &bgr;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: ApplicationFiled: February 22, 2002Publication date: September 19, 2002Applicant: NABIInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6355625Abstract: Compositions and kits comprising combinations of &bgr;-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which &bgr;-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: GrantFiled: September 14, 1999Date of Patent: March 12, 2002Assignee: NabiInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20020004208Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: February 16, 2001Publication date: January 10, 2002Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6232082Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 1, 1998Date of Patent: May 15, 2001Assignee: NabiInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso